Long-term safety and effectiveness of lubiprostone, a chloride channel (ClC-2) activator, in patients with chronic idiopathic constipation
about
Guidelines for the Diagnosis and Treatment of Chronic Functional Constipation in Korea, 2015 Revised EditionRecent Updates on the Treatment of ConstipationA critical appraisal of lubiprostone in the treatment of chronic constipation in the elderlyTreatment for constipation: new and old pharmacological strategiesLow-volume versus high-volume initiated trans-anal irrigation therapy in adults with chronic constipation: study protocol for a randomised controlled trial.Understanding and treating refractory constipation.Current and emerging treatments for irritable bowel syndrome with constipation and chronic idiopathic constipation: focus on prosecretory agents.Treatment of Chronic Constipation: Prescription Medications and Surgical Therapies.Lubiprostone in constipation: clinical evidence and place in therapy.What's New in the Toolbox for Constipation and Fecal Incontinence?A randomized, placebo-controlled trial of lubiprostone for opioid-induced constipation in chronic noncancer pain.Advancing treatment options for chronic idiopathic constipation.Targeting Ion Channels: An Important Therapeutic Implication in Gastrointestinal Dysmotility in Patients With Spinal Cord InjuryLubiprostone induced ischemic colitis.Linaclotide (Linzess) for Irritable Bowel syndrome With Constipation and For Chronic Idiopathic ConstipationNovel pharmacological therapies for management of chronic constipation.Habit training versus habit training with direct visual biofeedback in adults with chronic constipation: study protocol for a randomised controlled trial.Medical and surgical management of pelvic floor disorders affecting defecation.Safety evaluation of lubiprostone in the treatment of constipation and irritable bowel syndrome.Pharmacokinetic and pharmacodynamic considerations for the current chronic constipation treatments.Emerging treatments for chronic constipation.The safety of novel drugs used to treat irritable bowel syndrome.Phase II drugs under clinical investigation for the treatment of chronic constipation.Management of constipation in Parkinson's disease.Analysis of Nausea in Clinical Studies of Lubiprostone for the Treatment of Constipation Disorders.Constipation: Pathophysiology and Current Therapeutic Approaches.Diagnosis and management of chronic constipation in adults.A Randomized, Double-Blind, Placebo-Controlled Trial to Examine the Effectiveness of Lubiprostone on Constipation Symptoms and Colon Transit Time in Diabetic Patients.Role of lubiprostone on gastrointestinal motility.Long-Term Safety and Efficacy of Lubiprostone in Opioid-induced Constipation in Patients with Chronic Noncancer Pain.The Cost Effectiveness of Lubiprostone in Chronic Idiopathic Constipation.Stepped-wedge randomised trial of laparoscopic ventral mesh rectopexy in adults with chronic constipation: study protocol for a randomized controlled trial.Recent advances in understanding and managing chronic constipation
P2860
Q26745952-B1AD6778-C2A6-410F-A537-AC686DE1EA8CQ26820242-B6843559-46C9-4DE7-B9A0-2DAC5664D016Q26824999-77BBB5CF-8650-40AE-8F40-BE5D14677A1CQ27027346-47E121A6-3ECF-437D-9031-692834C5B659Q30843437-FD2A0F5F-D575-4D4C-8FDC-26A5147A20D1Q33621273-DF5DBFAC-E80D-4E78-843B-1250830EC7EEQ34478089-2562FFD6-C261-4519-A991-B598439B6DA2Q34522966-276A11F6-048B-463D-B96C-1D93BCE5310EQ35091370-50809FFA-F02E-4A9D-A39D-57329C4718CAQ35104452-AB46475F-5ED5-41C9-AA65-BCC4866270D7Q35583262-611745B2-D533-42B0-AA23-BFE6ED512748Q35858864-35BDA6A5-9C29-4534-AE3B-76149C6B223BQ36211724-76536527-4288-43E3-B9F2-E96202972D5FQ36541185-B3D8D52E-8A95-423E-9F18-834AC48B9D90Q36801233-93DD5A98-E3C3-48BD-8EC8-D88CB10E8249Q37394824-C8B730B5-57CA-412D-8705-40CF44ADD1BAQ37720888-95FA6F69-60D2-4AC3-9471-8E4842B62E7BQ37724871-442C40AF-B2A6-48F7-B2BB-6751D0111C1CQ38029718-558E2306-6B4B-416D-9A6D-725AC162C8A1Q38083079-0F698818-AC21-4A6E-8747-6443DA13578EQ38129960-05A44661-2015-4545-9FBC-D6901FAAEA14Q38199522-9BF03D84-D6AC-4C02-A818-59478B69C6BEQ38222819-18CB8A5B-F484-45E8-BCB5-08A7B6AD8469Q38300388-246914EB-75A5-4C5C-A8D8-01192CECEE2BQ38604426-E1650249-9A52-4D39-8B6E-F79EE5FD5FB7Q38759113-E156A66C-6768-47E3-BFEA-476234874908Q38794996-E82885C3-E410-4B4A-AF9B-B4E9B2DE09B3Q39127517-733F5D2A-3386-4F38-806E-0CCDFA4FF926Q41811753-74A0E46F-592D-41DE-8EF3-2A4D74C7BAE5Q44331744-621EF231-9F0C-4097-A9B5-4EE325355C97Q47179802-9F51D264-2668-4BB2-A5B6-7249E2CF253EQ48103733-306B5665-FA72-475D-BA55-01CEC706B550Q58562464-FD9CB186-A48A-413B-940C-ECCBB6B8B288
P2860
Long-term safety and effectiveness of lubiprostone, a chloride channel (ClC-2) activator, in patients with chronic idiopathic constipation
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Long-term safety and effective ...... hronic idiopathic constipation
@ast
Long-term safety and effective ...... hronic idiopathic constipation
@en
type
label
Long-term safety and effective ...... hronic idiopathic constipation
@ast
Long-term safety and effective ...... hronic idiopathic constipation
@en
prefLabel
Long-term safety and effective ...... hronic idiopathic constipation
@ast
Long-term safety and effective ...... hronic idiopathic constipation
@en
P2093
P2860
P1476
Long-term safety and effective ...... hronic idiopathic constipation
@en
P2093
Anthony J Lembo
Henry P Parkman
John F Johanson
Philip B Miner
Ryuji Ueno
Satish S Rao
P2860
P2888
P304
P356
10.1007/S10620-011-1801-0
P577
2011-07-19T00:00:00Z